Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.81 USD
Change Today +0.69 / 3.27%
Volume 2.7M
HZNP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma plc (HZNP) Snapshot

Open
$21.20
Previous Close
$21.12
Day High
$21.92
Day Low
$21.16
52 Week High
03/20/15 - $23.45
52 Week Low
07/29/14 - $7.85
Market Cap
2.9B
Average Volume 10 Days
2.8M
EPS TTM
$0.05
Shares Outstanding
132.1M
EX-Date
--
P/E TM
435.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for HORIZON PHARMA PLC (HZNP)

horizon pharma plc (HZNP) Related Businessweek News

No Related Businessweek News Found

horizon pharma plc (HZNP) Details

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA of the knee; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS). The company also provides RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.

535 Employees
Last Reported Date: 03/2/15
Founded in 2005

horizon pharma plc (HZNP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $589.2K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $396.3K
Consultant
Total Annual Compensation: $374.9K
Compensation as of Fiscal Year 2013.

horizon pharma plc (HZNP) Key Developments

Horizon Pharma Mulls Acquisition

Horizon Pharma plc (NasdaqGS:HZNP) is seeking acquisition. Horizon Pharma plc closed offering of $400 million of 2.50% exchangeable senior notes and expects to use the proceed from the offering for for general corporate purposes and to fund future acquisitions or investments in businesses, products and product candidates, although Horizon has no present commitments or agreements to do so.

Horizon Pharma plc Announces Pre-Clinical Data Show Treatment with Interferon Gamma Improved Signs of Disease Severity of Rare Bone Disease

Horizon Pharma plc announced that pre-clinical data from an investigator initiated study demonstrated that treatment with murine interferon gamma, which is an analogue of interferon gamma-1b (ACTIMMUNE), improved the signs of disease severity in a mouse model of Autosomal Dominant Osteopetrosis Type II (ADO2). Osteopetrosis is typically divided into two categories: autosomal recessive osteopetrosis or severe malignant osteopetrosis and autosomal dominant osteopetrosis (further divided into Type I and II (ADO2)). ADO2 is a rare, inherited disease resulting from a gene mutation that, despite an increased bone mass, is characterized by a wide range of symptoms and severity including multiple fractures, impaired vision and osteomyelitis (bone infection). ADO2 is the most common type of Autosomal Dominant Osteopetrosis with an estimated prevalence of up to 5.5 per 100,000. This disease has limited treatment options and as reflected in this study, treatment with calcitriol has not resulted in much clinical improvement. The pre-clinical study evaluated the effect of murine interferon gamma in a knock-in mouse model of the p.G213R mutation in the murine CLCN7 gene that results in severe osteopetrosis and death in homozygous (identical gene pairs) mice and a moderately severe form of osteopetrosis in heterozygous (different gene pairs) mice. Mice (n=10/group) were administered either placebo or varying doses (low, medium, high) of interferon gamma or calcitriol (a form of vitamin D) five times per week for 8 weeks. At the end of the eight-week treatment, X-ray and microcomputed tomography showed that treatment with interferon gamma significantly (p < 0.005) reduced the increase of whole body areal bone mineral density, an important measure of bone strength, across all dosing regimens in both male and female ADO2 mice compared to the vehicle group. Additionally, interferon gamma treatment significantly reduced (p < 0.05) the bone volume over tissue volume gain across all dosing regimens in both male and female ADO2 mice compared to the vehicle group. In contrast, mice treated with low and medium doses of calcitriol showed a trend of higher bone mass including whole body areal bone mineral density and bone volume over tissue volume gain whereas the high dose calcitriol group significantly increased areal bone mineral density and bone volume over tissue volume gain compared to the placebo group. Autosomal Dominant Osteopetrosis Type II is a devastating disease and while these data are early, the findings may be important in exploring future treatment. ACTIMMUNE is approved for severe malignant osteopetrosis, the autosomal recessive form, and often the most severe form of osteopetrosis. Horizon is committed to exploring the full clinical utility of ACTIMMUNE and furthering potential treatment options where unmet needs exist for patients with osteopetrosis.

Horizon Pharma plc Prices Offering of $350 Million of 2.50% Exchangeable Senior Notes

Horizon Pharma plc priced its offering of $350 million aggregate principal amount of Exchangeable Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The size of the offering was increased from the previously announced $300 million aggregate principal amount. The Issuer has also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50 million aggregate principal amount of the notes. The sale of the notes is expected to close on March 13, 2015, subject to customary closing conditions. The Issuer expects that the net proceeds from this offering will be approximately $338.0 million, after deducting the initial purchasers' discount and estimated offering expenses payable by the Issuer. The notes will be general unsecured senior obligations of the Issuer and accrue interest at an annual rate of 2.50% payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2015. The notes will mature on March 15, 2022, unless earlier exchanged, repurchased or redeemed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $21.81 USD +0.69

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $90.04 USD +2.23
Pfizer Inc $34.53 USD +0.37
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.5x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit www.horizonpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.